Aurobindo Pharma Share Price
Sector: Major Drugs
1124.75 +1.60 (0.14%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1119.50
Today’s High
1138.45
52 Week Low
994.35
52 Week High
1592.55
1121.00 -2.20 (-0.20%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1119.00
Today’s High
1138.80
52 Week Low
1010.00
52 Week High
1592.00
Key Metrics
- Market Cap (In Cr) 65325.66
- Beta 0.77
- Div. Yield (%) 0
- P/B 2
- TTM P/E 19.4
- Peg Ratio 1.92
- Sector P/E 22.67
- D/E 0
- Open Price 1125.1
- Prev Close 1123.15
Aurobindo Pharma Analysis
Price Analysis
-
1 Week3.76%
-
3 Months-3.53%
-
6 Month-10.59%
-
YTD-15.83%
-
1 Year-6.24%
Risk Meter
- 33% Low risk
- 33% Moderate risk
- 33% Balanced Risk
- 33% High risk
- 33% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 9
- 8
- 11
- 10
- Buy
- 12
- 12
- 9
- 9
- Hold
- 1
- 1
- 1
- 2
- Sell
- 2
- 2
- 2
- 2
- Strong Sell
- 2
- 2
- 2
- 2
- Total
- 26
- 25
- 25
- 25
Aurobindo Pharma News
Gland Pharma, Cipla among 8 stocks that jumped up to 28% since April
3 min read . 06 Jun 2025Lupin, Aurobindo among Axis Sec's top pharma & hospital picks post strong Q4
2 min read . 05 Jun 2025Aurobindo Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 31723.73
- Selling/ General/ Admin Expenses Total
- 4475.62
- Depreciation/ Amortization
- 1649.42
- Other Operating Expenses Total
- 7616.43
- Total Operating Expense
- 26767.71
- Operating Income
- 4956.02
- Net Income Before Taxes
- 5066.29
- Net Income
- 3485.88
- Diluted Normalized EPS
- 59.81
- Period
- 2025
- Total Assets
- 49784.97
- Total Liabilities
- 17131.65
- Total Equity
- 32653.32
- Tangible Book Valueper Share Common Eq
- 489.23
- Period
- 2025
- Cashfrom Operating Activities
- 3925.28
- Cashfrom Investing Activities
- -1875.8
- Cashfrom Financing Activities
- 119.78
- Net Changein Cash
- 2178.36
- Period
- 2024
- Total Revenue
- 29001.87
- Selling/ General/ Admin Expenses Total
- 8858.87
- Depreciation/ Amortization
- 1491.91
- Other Operating Expenses Total
- 530.61
- Total Operating Expense
- 24871.4
- Operating Income
- 4130.47
- Net Income Before Taxes
- 4379.99
- Net Income
- 3172.97
- Diluted Normalized EPS
- 57
- Period
- 2024
- Total Assets
- 45071.51
- Total Liabilities
- 15228.71
- Total Equity
- 29842.8
- Tangible Book Valueper Share Common Eq
- 439.74
- Period
- 2024
- Cashfrom Operating Activities
- 2434.52
- Cashfrom Investing Activities
- -4255.95
- Cashfrom Financing Activities
- 800.42
- Net Changein Cash
- -1006.84
- Period
- 2023
- Total Revenue
- 24855.38
- Selling/ General/ Admin Expenses Total
- 8189.45
- Depreciation/ Amortization
- 1244.58
- Other Operating Expenses Total
- 518.34
- Total Operating Expense
- 22341.74
- Operating Income
- 2513.64
- Net Income Before Taxes
- 2612.5
- Net Income
- 1927.5
- Diluted Normalized EPS
- 33.03
- Period
- 2023
- Total Assets
- 39889.99
- Total Liabilities
- 13050.14
- Total Equity
- 26839.85
- Tangible Book Valueper Share Common Eq
- 391.13
- Period
- 2023
- Cashfrom Operating Activities
- 2393.16
- Cashfrom Investing Activities
- -3977.75
- Cashfrom Financing Activities
- 1814.41
- Net Changein Cash
- 229.76
- Period
- 2022
- Total Revenue
- 23455.49
- Selling/ General/ Admin Expenses Total
- 7593.01
- Depreciation/ Amortization
- 1126.52
- Other Operating Expenses Total
- 316.95
- Total Operating Expense
- 20399.22
- Operating Income
- 3056.27
- Net Income Before Taxes
- 3372.74
- Net Income
- 2648.15
- Diluted Normalized EPS
- 47.45
- Period
- 2022
- Total Assets
- 33921.72
- Total Liabilities
- 9345.74
- Total Equity
- 24575.98
- Tangible Book Valueper Share Common Eq
- 357.76
- Period
- 2022
- Cashfrom Operating Activities
- 5013.23
- Cashfrom Investing Activities
- -3211.56
- Cashfrom Financing Activities
- -2969.27
- Net Changein Cash
- -1167.4
- Period
- 2021
- Total Revenue
- 24774.62
- Selling/ General/ Admin Expenses Total
- 8108.66
- Depreciation/ Amortization
- 1055.39
- Other Operating Expenses Total
- 317.35
- Total Operating Expense
- 17540.91
- Operating Income
- 7233.71
- Net Income Before Taxes
- 7343.59
- Net Income
- 5334.84
- Diluted Normalized EPS
- 57.91
- Period
- 2021
- Total Assets
- 33853.99
- Total Liabilities
- 11924.12
- Total Equity
- 21929.87
- Tangible Book Valueper Share Common Eq
- 321.03
- Period
- 2021
- Cashfrom Operating Activities
- 3351.33
- Cashfrom Investing Activities
- 598.69
- Cashfrom Financing Activities
- -1364.81
- Net Changein Cash
- 2583.09
- Period
- 2020
- Total Revenue
- 23098.51
- Selling/ General/ Admin Expenses Total
- 7099.39
- Depreciation/ Amortization
- 966.71
- Other Operating Expenses Total
- 364.07
- Total Operating Expense
- 19190
- Operating Income
- 3908.51
- Net Income Before Taxes
- 3743.04
- Net Income
- 2845.14
- Diluted Normalized EPS
- 49.38
- Period
- 2020
- Total Assets
- 28927.74
- Total Liabilities
- 12103.07
- Total Equity
- 16824.67
- Tangible Book Valueper Share Common Eq
- 231.4
- Period
- 2020
- Cashfrom Operating Activities
- 4381.28
- Cashfrom Investing Activities
- -1567.64
- Cashfrom Financing Activities
- -1947.18
- Net Changein Cash
- 871.24
- Period
- 2019
- Total Revenue
- 19563.55
- Selling/ General/ Admin Expenses Total
- 5628.36
- Depreciation/ Amortization
- 667.95
- Other Operating Expenses Total
- 338.59
- Total Operating Expense
- 16348.13
- Operating Income
- 3215.42
- Net Income Before Taxes
- 3091.35
- Net Income
- 2364.73
- Diluted Normalized EPS
- 41.76
- Period
- 2019
- Total Assets
- 26454.36
- Total Liabilities
- 12563.58
- Total Equity
- 13890.78
- Tangible Book Valueper Share Common Eq
- 184.04
- Period
- 2019
- Cashfrom Operating Activities
- 1650.97
- Cashfrom Investing Activities
- -2902.59
- Cashfrom Financing Activities
- 1919.06
- Net Changein Cash
- 665.64
- Period
- 2025-03-31
- Total Revenue
- 8382.12
- Selling/ General/ Admin Expenses Total
- 1162.64
- Depreciation/ Amortization
- 444.43
- Other Operating Expenses Total
- 1999.68
- Total Operating Expense
- 7034.63
- Operating Income
- 1347.49
- Net Income Before Taxes
- 1335.09
- Net Income
- 903.47
- Diluted Normalized EPS
- 15.56
- Period
- 2025-03-31
- Total Assets
- 49784.97
- Total Liabilities
- 17131.65
- Total Equity
- 32653.32
- Tangible Book Valueper Share Common Eq
- 489.23
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 3925.28
- Cashfrom Investing Activities
- -1875.8
- Cashfrom Financing Activities
- 119.78
- Net Changein Cash
- 2178.36
- Period
- 2024-12-31
- Total Revenue
- 7978.52
- Selling/ General/ Admin Expenses Total
- 1131.55
- Depreciation/ Amortization
- 418.53
- Other Operating Expenses Total
- 1903.75
- Total Operating Expense
- 6769.24
- Operating Income
- 1209.28
- Net Income Before Taxes
- 1199.85
- Net Income
- 845.81
- Diluted Normalized EPS
- 14.56
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 7796.07
- Selling/ General/ Admin Expenses Total
- 1109.48
- Depreciation/ Amortization
- 382.28
- Other Operating Expenses Total
- 1910.18
- Total Operating Expense
- 6612.21
- Operating Income
- 1183.86
- Net Income Before Taxes
- 1207.46
- Net Income
- 817.38
- Diluted Normalized EPS
- 14
- Period
- 2024-09-30
- Total Assets
- 48094.45
- Total Liabilities
- 17216.06
- Total Equity
- 30878.39
- Tangible Book Valueper Share Common Eq
- 462.63
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 653.08
- Cashfrom Investing Activities
- -708.22
- Cashfrom Financing Activities
- 545.22
- Net Changein Cash
- 510.88
- Period
- 2024-06-30
- Total Revenue
- 7567.02
- Selling/ General/ Admin Expenses Total
- 1071.95
- Depreciation/ Amortization
- 404.18
- Other Operating Expenses Total
- 1802.82
- Total Operating Expense
- 6351.63
- Operating Income
- 1215.39
- Net Income Before Taxes
- 1323.89
- Net Income
- 919.22
- Diluted Normalized EPS
- 15.69
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 7580.15
- Selling/ General/ Admin Expenses Total
- 1026.32
- Depreciation/ Amortization
- 354.33
- Other Operating Expenses Total
- 1805.86
- Total Operating Expense
- 6369.5
- Operating Income
- 1210.65
- Net Income Before Taxes
- 1229.9
- Net Income
- 908.75
- Diluted Normalized EPS
- 17.1
- Period
- 2024-03-31
- Total Assets
- 45071.51
- Total Liabilities
- 15228.71
- Total Equity
- 29842.8
- Tangible Book Valueper Share Common Eq
- 439.74
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 2434.52
- Cashfrom Investing Activities
- -4255.95
- Cashfrom Financing Activities
- 800.42
- Net Changein Cash
- -1006.84
- Period
- 2023-12-31
- Total Revenue
- 7351.78
- Selling/ General/ Admin Expenses Total
- 989.68
- Depreciation/ Amortization
- 423.27
- Other Operating Expenses Total
- 1610.22
- Total Operating Expense
- 6173.74
- Operating Income
- 1178.04
- Net Income Before Taxes
- 1262.42
- Net Income
- 936.29
- Diluted Normalized EPS
- 16.04
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Aurobindo Pharma Technical
Moving Average
SMA
- 5 Day1098.05
- 10 Day1120.95
- 20 Day1137.45
- 50 Day1173.56
- 100 Day1154.82
- 300 Day1256.56
Aurobindo Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Aurobindo Pharma
- 1124.75
- 1.6
- 0.14
- 1592.55
- 994.35
- 65325.66
- Pfizer
- 5701
- 27.65
- 0.49
- 6452.85
- 3742.9
- 26313.14
- Astrazeneca Pharma India
- 8904.1
- 165.75
- 1.9
- 10653.05
- 6160.25
- 22260.25
- Neuland Laboratories
- 12105
- 143.95
- 1.2
- 18089.55
- 6552
- 15515.22
- Unichem Laboratories
- 594.95
- -2.6
- -0.44
- 949.85
- 510.8
- 4191.23
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Aurobindo Pharma
- 18.73
- 1.99
- 12.95
- 12.38
- Pfizer
- 40.02
- 6.04
- 19.24
- 25.99
- Astrazeneca Pharma India
- 118.02
- 28.71
- 18.74
- 9.43
- Neuland Laboratories
- 76.08
- 10.11
- 17.29
- 14.2
- Unichem Laboratories
- 30.83
- 1.72
- -0.54
- -0.88
Aurobindo Pharma Shareholding
Shareholding Pattern
*Promoter pledging: 8.77%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 26-May-25
- Audited Results
- 06-Feb-25
- Quarterly Results
- 09-Nov-24
- Quarterly Results
- 10-Aug-24
- Quarterly Results
- 18-Jul-24
- Buy Back of Shares
- 25-May-24
- Audited Results
- 10-Feb-24
- Quarterly Results & Interim Dividend
- 09-Nov-23
- Quarterly Results & Interim Dividend
- 12-Aug-23
- Quarterly Results
- 27-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 20-Mar-25
- 13-Feb-25
- POM
- 29-Aug-24
- 31-Jul-24
- AGM
- 28-Mar-24
- 22-Feb-24
- POM
- 28-Dec-23
- 24-Nov-23
- POM
- 25-Aug-23
- 28-Jul-23
- AGM
- 23-Mar-23
- 17-Feb-23
- POM
- 02-Aug-22
- 07-Jul-22
- AGM
- 12-Feb-22
- 12-Jan-22
- POM
- 26-Aug-21
- 03-Aug-21
- AGM
- 27-Aug-20
- 03-Aug-20
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 07-Feb-24
- 20-Feb-24
- 20-Feb-24
- 1.5
- 02-Nov-23
- 20-Nov-23
- 20-Nov-23
- 3
- 03-Feb-23
- 17-Feb-23
- 17-Feb-23
- 3
- 20-May-22
- 07-Jun-22
- 06-Jun-22
- 4.5
- 09-Feb-22
- 21-Feb-22
- 18-Feb-22
- 1.5
- 08-Nov-21
- 18-Nov-21
- 17-Nov-21
- 1.5
- 12-Aug-21
- 30-Aug-21
- 27-Aug-21
- 1.5
- 10-Feb-21
- 23-Feb-21
- 22-Feb-21
- 1.5
- 11-Nov-20
- 24-Nov-20
- 23-Nov-20
- 1.25
- 12-Aug-20
- -
- 21-Aug-20
- 1.25


